Anti-programmed cell death-1 therapy in nonmelanoma skin cancer

A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor

(2016) Anne Lynn S. Chang et al.   JAMA Dermatology

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers

(2015) B Homet Moreno et al.   BRITISH JOURNAL OF CANCER

Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort.

(2015) Tanguy Y. Seiwert et al.   JOURNAL OF CLINICAL ONCOLOGY

Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial

(2015) Nicole Basset-Seguin et al.   LANCET ONCOLOGY

Mutant MHC class II epitopes drive therapeutic immune responses to cancer

(2015) Sebastian Kreiter et al.   NATURE

Sarcoidosis in Melanoma Patients: Case Report and Literature Review

(2015) Bryce Beutler et al.   Cancers

The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy

(2014) Simone Muenst et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma

(2014) Sabrina Pricl et al.   Molecular Oncology

PD-1 blockage delays murine squamous cell carcinoma development

(2013) E. B. Belai et al.   CARCINOGENESIS

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Immunotherapy in nonmelanoma skin cancer

(2012) Soudeh Ghafouri-Fard et al.   Immunotherapy

Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma

(2008) Ahmad Jalili et al.   JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT